A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs (ANDROMEDA)

AstraZeneca

Status and phase: Not yet enrolling; Phase 2; Phase 1

Conditions: Prostate Cancer

Treatments: Drug: AZD5305; Drug: AZD9750

Study type: Interventional

Funder types: Industry

Identifiers

NCT07336446

D7270C00001

Details and patient eligibility

About

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.

Full description

This first-in-human (FiH), Phase I/II, open-label, multicenter study will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib in participants with metastatic prostate cancer. Additional combinations with other anticancer agents may be added via protocol amendment as separate modules. The study follows a modular design, allowing initial assessment of safety, tolerability, and preliminary efficacy across multiple treatment arms. Each Module has 2 parts: Part A (monotherapy dose escalation or combination dose finding) and Part B (monotherapy dose optimization and expansion or combination dose expansion). Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention occur.

Enrollment: 300 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Inclusion Criteria:

  • Participant must be ≥18 years or the legal age at the time of signing the informed consent form.

  • Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate.

  • Documented metastatic disease.

  • Serum testosterone levels ≤ 50 ng/dL.

  • Evidence of disease progression with one of the following:

    1. PSA progression defined by a minimum of 3 rising PSA levels with an interval of ≥ 1 week between each determination.
    2. Radiographic progression of soft tissue disease by RECIST v1.1 with or without PSA progression.
    3. Radiographic progression of bone metastasis with 2 or more documented new bone lesions on a bone scan with or without PSA progression.

  • ECOG performance status score of 0 or 1.

  • Adequate bone marrow and organ function.

  • Part A (Module 1)

    • (a) Part A1 dose escalation: at least 1 prior ARPI and, if applicable, at least 1 taxane-based chemotherapy (regardless of whether in HSPC or CRPC setting).
    • (b) Part A2 backfill: at least 1 but no more than 2 prior ARPIs and, if applicable, at least 1 but no more than 2 prior taxane-based chemotherapies (regardless of whether in HSPC or CRPC setting).

  • Part B (Module 1)

    • (a) B1/B2 dose optimization/expansion: at least 1 but no more than 2 prior ARPIs and, if applicable, at least 1 but no more than 2 prior taxane-based chemotherapies (regardless of whether in HSPC or CRPC setting).
    • (b) B3 dose expansion (no taxane cohort): at least 1 but no more than 2 prior ARPIs for metastatic prostate cancer (regardless of whether in HSPC or CRPC setting). No prior taxane is allowed for inclusion in this cohort.

• Exclusion Criteria:

  • Participants with pathological finding consistent with any presence of small cell carcinoma, predominant neuroendocrine carcinoma, or any predominant histology other than prostate adenocarcinoma.
  • Brain metastases, or spinal cord compression.
  • Any clinically significant cardiac disorders including QT prolongation, abnormal electrocardiogram (ECG).
  • Any clinically significant cardiovascular diseases including symptomatic heart failure, uncontrolled hypertension, acute coronary syndrome, cardiomyopathy, valvular heart disease, atrial fibrillation, stroke.
  • Active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism of AZD9750 and relevant combination IMPs.
  • Participants with any known predisposition to bleeding (eg, active peptic ulceration, recent [within 6 months] hemorrhagic stroke, proliferative diabetic retinopathy).
  • Prior treatment with an AR-PROTAC.

Other protocol-defined inclusion/exclusion criteria apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

300 participants in 7 patient groups

Module 1 / Part A1

Experimental group

Description:

AZD9750 Monotherapy (Dose Escalation) - No randomization

Treatment:

Drug: AZD9750

Module 1 / Part A2

Experimental group

Description:

AZD9750 Monotherapy (Backfills) - No randomization

Treatment:

Drug: AZD9750

Module 1 / Part B1

Experimental group

Description:

AZD9750 Monotherapy (Dose Optimization) - Randomization

Treatment:

Drug: AZD9750

Module 1 Part B2

Experimental group

Description:

AZD9750 Monotherapy (Dose Expansion) - No randomization

Treatment:

Drug: AZD9750

Module 1 / Part B3

Experimental group

Description:

AZD9750 Monotherapy (Dose Expansion) - No randomization

Treatment:

Drug: AZD9750

Module 2 / Part A

Experimental group

Description:

AZD9750 + Saruparib (Combination Dose Finding) - No Randomization

Treatment:

Drug: AZD9750

Drug: AZD5305

Module 2/ Part B

Experimental group

Description:

AZD9750 + Saruparib (Combination Dose Expansion) - No Randomization

Treatment:

Drug: AZD9750

Drug: AZD5305